SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Coming soon · Friday 13 November · 09:45 CET

The International Lung Cancer Summit 2026

Live Summit5 CME credits · EACCME & SSMO

Event details

The International Lung Cancer Summit 2026

Led by global experts

The people in the room

A global roster of oncologists, surgeons and pathologists — chaired from Lausanne, drawn from across the field.

Solange Peters

Chair, Switzerland

Alfredo Addeo

Chair, Switzerland

Umberto Malapelle

Italy

Hidehito Horinouchi

Japan

Telma Sequeira

Portugal

Christine Lovly

USA

David Planchard

France

Sandip Patel

USA

Giannis Mountzios

Greece

Anne-Marie Dingemans

Netherlands

Where we meet · Lausanne

On site & online

Hosted at CHUV in Lausanne and live-streamed worldwide — join in person, or from your own clinic.

VenueCHUV · Bâtiment AGORA
AddressRue du Bugnon 25A, 1005 Lausanne
DateFri 13 Nov 2026 · 9:45 CET
FormatHybrid · live-streamed · CME-certified
Get Directions

ILCS · In frames

Last year, in Lausanne

A day on the ground — faculty, debate and the room between sessions.

JOIN US IN LAUSANNE, SWITZERLAND

Browse Our 2024 Gallery

See Some Impressions Here

Mark Your Calendar

View Full Program

       Continue With

Related Topics

Jul 09 2026

Advances in EGFR+ NSCLC

[et_pb_section fb_built="1" admin_label="section" _builder_version="4.16" global_colors_info="{}"][et_pb_row admin_label="row" _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="...
O. Gautschi
Jul 05 2026

Targeted Therapies in NSCLC

O. GautschiJ. NaidooN. GirardZ. Piotrowska
Jul 05 2026

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A recorded symposium from ESMO Congress 2026, tracing small-cell lung cancer treatment from immunotherapy standards to the emerging era of DLL3 T-cell engagers. The recording is published here after the ...

M. ReckS. PetersG. MountziosN. Reguart
Apr 15 2026
TARGETED THERAPIES
Metastatic NSCLCTargeted Therapies

Targeted Therapies in Metastatic NSCLC: Reshaping First-Line Choice

Five next-generation TKIs have rewritten first-line choice in driver-positive metastatic NSCLC. This update distils which biomarker matters, when CNS coverage drives the pick, and where the field is heading ...
Mar 22 2026
ADCs
BiomarkersSCLCADCs

ADCs in Small Cell Lung Cancer: An Emerging Class

Antibody-drug conjugates are arriving in SCLC after a decade of failed cytotoxics. Three platforms — DLL3, B7-H3, and SEZ6 — now have phase-2 readouts. This update...
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
Metastatic NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
SCLC

RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE

} 34 min

R. Manochakian
Sep 26 2025
Metastatic NSCLC

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

} 32 min

A. Curioni
Sep 26 2025
Immunotherapies

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

} 28 min

A. Filippi
Sep 26 2025
Immunotherapies

TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Metastatic NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni
Sep 26 2025
INDUSTRY SYMPOSIUM
Metastatic NSCLCTargeted Therapies

UNLOCKING NEW POTENTIALS IN EGFR-MUTANT NSCLC

} 30 min

A. Passaro
Sep 26 2025
ADCs

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

} 27 min

N. Reguart
Sep 26 2025
Targeted Therapies

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

} 31 min
Sep 26 2025
Targeted Therapies

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

} 26 min

S. Saw
Sep 26 2025
Targeted Therapies

TARGETING EGFR AND ALK IN NSCLC

} 26 min

T. John
Sep 26 2025
Biomarkers

CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS

} 24 min

M. Ilié
Sep 26 2025
Metastatic NSCLC

Open Discussion on Patient Cases

} 22 min
Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
Metastatic NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
Metastatic NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates